Literature DB >> 10570421

Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses.

K Suzuki1, K Nagai, J Yoshida, M Nishimura, K Takahashi, T Yokose, Y Nishiwaki.   

Abstract

BACKGROUND: A number of prognostic factors have been reported for resected nonsmall cell lung carcinoma. None of them, however, has been reported to have greater prognostic impact than the pathologic TNM staging system. The authors evaluated 18 conventional clinicopathologic prognostic factors in each pathologic stage.
METHODS: A retrospective study was conducted on surgically resected 836 lung carcinoma patients, and the following conventional prognostic factors were evaluated in multivariate analyses: age, gender, pack-year smoking, serum carcinoembryonic antigen and squamous cell carcinoma antigen levels, laterality of tumor, clinical N status, histologic type of tumor, greatest tumor dimension, grade of differentiation, pleural involvement, lymphatic invasion, vascular invasion, degree of fibrosing scarring, nuclear atypia, mitotic activity, and curativity of resection.
RESULTS: The overall 5-year survival rate was 63.8%. In 430 cases of pathologic Stage I disease, multivariate analyses revealed 3 significant prognostic factors: clinical N status (P < 0.001), vascular invasion (P = 0.001), and curativity of resection (P < 0.001). In 406 cases of more advanced disease, i.e., pathologic Stage II, IIIA, IIIB, or IV, multivariate analyses revealed 4 factors as significant: histology (P = 0.001), pathologic N status (P < 0.001), tumor size (P < 0.001), and curativity of resection (P = 0.002).
CONCLUSIONS: Conventional clinicopathologic prognostic factors had a different impact on prognosis in each pathologic TNM stage among patients who underwent surgical resection of nonsmall cell lung carcinoma. These factors should be analyzed separately in each pathologic TNM stage. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Year:  1999        PMID: 10570421     DOI: 10.1002/(sici)1097-0142(19991115)86:10<1976::aid-cncr14>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  Discriminating lung adenocarcinoma from lung squamous cell carcinoma using respiration-induced tumor shape changes.

Authors:  Yi Lao; John David; Amin Mirhadi; Natasha Lepore; Howard Sandler; Yalin Wang; Richard Tuli; Wensha Yang
Journal:  Phys Med Biol       Date:  2018-11-07       Impact factor: 3.609

2.  Low perioperative serum prealbumin predicts early recurrence after curative pulmonary resection for non-small-cell lung cancer.

Authors:  Hideki Kawai; Hideki Ota
Journal:  World J Surg       Date:  2012-12       Impact factor: 3.352

3.  How close are we to customizing chemotherapy in early non-small cell lung cancer?

Authors:  Georgios Ioannidis; Vassilis Georgoulias; John Souglakos
Journal:  Ther Adv Med Oncol       Date:  2011-07       Impact factor: 8.168

4.  Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables.

Authors:  Thierry Berghmans; Marianne Paesmans; Jean-Paul Sculier
Journal:  Ther Adv Med Oncol       Date:  2011-05       Impact factor: 8.168

5.  Clinical usefulness of D2-40 in non-small cell lung cancer.

Authors:  Kyung Hoon Min; Seoung Ju Park; Kyung Sun Lee; Sung Ho Hwang; So Ri Kim; Hee Moon; Hyo Jin Han; Myoung Ja Chung; Yong Chul Lee
Journal:  Lung       Date:  2010-11-25       Impact factor: 2.584

6.  Prognostic stratification of patients with T3N1M0 non-small cell lung cancer: which phase should it be?

Authors:  Ali Kilicgun; Ozgur Tanriverdi; Akif Turna; Muzaffer Metin; Adnan Sayar; Okan Solak; Nur Urer; Atilla Gurses
Journal:  Med Oncol       Date:  2011-03-24       Impact factor: 3.064

7.  Podoplanin in cancer cells is experimentally able to attenuate prolymphangiogenic and lymphogenous metastatic potentials of lung squamoid cancer cells.

Authors:  Hanako Suzuki; Mitsuho Onimaru; Yoshikazu Yonemitsu; Yoshihiko Maehara; Seiji Nakamura; Katsuo Sueishi
Journal:  Mol Cancer       Date:  2010-10-31       Impact factor: 27.401

8.  Tumorigenic role of orphan nuclear receptor NR0B1 in lung adenocarcinoma.

Authors:  Tomofumi Oda; Tian Tian; Masayoshi Inoue; Jun-Ichiro Ikeda; Ying Qiu; Meinoshin Okumura; Katsuyuki Aozasa; Eiichi Morii
Journal:  Am J Pathol       Date:  2009-07-30       Impact factor: 4.307

9.  Clinical significance of vascular endothelial growth factors (VEGF)-C and -D in resected non-small cell lung cancer.

Authors:  Yoon Ho Ko; Chan-Kwon Jung; Myung-Ah Lee; Jae Ho Byun; Jin Hyoung Kang; Kyo Young Lee; Keon Hyun Jo; Young Pil Wang; Young Seon Hong
Journal:  Cancer Res Treat       Date:  2008-09-30       Impact factor: 4.679

10.  Predicting survival in potentially curable lung cancer patients.

Authors:  Thida Win; Linda Sharples; Ashley M Groves; Andrew J Ritchie; Francis C Wells; Clare M Laroche
Journal:  Lung       Date:  2008-02-09       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.